Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Ozempic (semaglutide) is a brand-name drug prescribed to treat certain conditions, such as type 2 diabetes. Ozempic has interactions with some other drugs, such as insulin, and certain supplements.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

The drug is now indicated specifically to treat kidney failure, prevent death from cardiovascular disease, and lower the risk of kidney disease. Ozempic is a glucagon-like peptide-1 (GLP-1 ...